Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class IITerminatedD-0282-2021

Drug recall · March 3, 2021

MethyIPREDNISolone Acetate Injectable Suspension USP recall

Why: Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Class II: could cause temporary or reversible health problems; serious harm is remote.

The recall

Product

MethyIPREDNISolone Acetate Injectable Suspension USP, 400 mg/10 mL (40 mg/mL), 10 mL Multiple-Dose Vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0703-0045-01.

Lots / codes

Lot # 31327725B, exp. date 02/2021 Lot # 31327906B, exp. date 03/2021

Quantity
N/A
Company
Teva Pharmaceuticals USA, Parsippany, NJ
Distribution
Product was distributed nationwide in the USA and Puerto Rico.
Initiated
February 10, 2021 · Voluntary: Firm initiated
Classified
February 21, 2021
Reported
March 3, 2021
Ended
May 15, 2024
How notified
Letter

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Recalled with it (same recall event)

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.